GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global MRSA industry . The report identifies the major industry developments shaping and driving the global MRSA industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global MRSA segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

The global MRSA industry was valued at USD 900m in 2010 and is projection to grow at a Compound Annual Growth Rate (CAGR) of 4.8% for the next seven years to reach USD 1,249m by 2017. The growth will primarily be driven by an increase in the average number of days spent in the hospitals due to inappropriate initial and steady increase in elderly amd immuno-suppressed population. At present the industry has six approved therapies, out of which Vancomycin and Synercid (Quinupristin+Dalfopristin) are generic and rest four are branded drugs. Currently, the industry is dominated by drugs like Vancomycin, Zyvox (linezolid) and Cubicin (daptomycin). As the disease is curable when identified in time, the unmet need seems to be low. Although the existing drugs such as Vancomycin, Zyvox, Cubicin, Tygacil (tygecycline), Vibativ (televancin) and Synercid are capable of curing the disease, still there are unmet needs which can be tapped with the emerging agents which have better safety.

Scope of the Research

The report provides data on the key drivers and challenges of the MRSA industry . Its Scope of the Research includes -
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) MRSA industry revenues data 2005-2010, projection for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates fall under major therapeutic classes such as Penicillin-binding proteins (PBPs) binders, Transglycosylation and Transpeptidation inhibitor, Pleuromutilin bacterial protein synthesis inhibitor, CYP3A4-specific inhibitors and Membrane lysing action.
- Analysis of the current and future competition in the seven key countries MRSA industry . Key industry players covered are Takeda Pharmaceutical Firms Limited/ Forest Laboratories, Merck & Co., Inc., Astrazeneca PLC, Trius Therapeutics, e-Therapeutics, Nabriva Therapeutics, TrioBiotics Pharma and Basilea Pharma.
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the MRSA therapeutics industry .
- Analysis of key recent licensing and partnership agreements in MRSA industry

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MRSA industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global MRSA industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global MRSA industry landscape? – Identify, understand and decide.

Table Of Contents

1 Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 5

II MRSA - Introduction 6
II. 1 Overview 6
II. 2 Pathophysiology of MRSA 7
II. 3 Epidemiology of MRSA 8
II. 4 Etiology of MRSA 8
II. 5 Symptoms of MRSA 8
II. 6 Diagnosis of MRSA 9
II. 7 Treatment and Management Pattern of MRSA 9
II. 8 GlobalData Pipeline Report Guidance 10

III MRSA Therapeutics - March ket Characterization 11
III. 1 MRSA, World March ket Size 11
III. 2 MRSA March ket Forecasted data and Compound Annual Growth Rate 12
III. 3 MRSA Therapeutics March ket - The US (2005-2010) 13
III. 4 MRSA Therapeutics March ket Forecasted data - The US (2010-2017) 14
III. 5 MRSA Therapeutics March ket - France (2005-2010) 15
III. 6 MRSA Therapeutics March ket Forecasted data - France (2010-2017) 16
III. 7 MRSA Therapeutics March ket - Germany (2005-2010) 17
III. 8 MRSA Therapeutics March ket Forecasted data - Germany (2010-2017) 18
III. 9 MRSA Therapeutics March ket - Spain (2005-2010) 19
III. 10 MRSA Therapeutics March ket Forecasted data - Spain (2010-2017) 20
III. 11 MRSA Therapeutics March ket - Italy (2005-2010) 21
III. 12 MRSA Therapeutics March ket Forecasted data - Italy (2010-2017) 22
III. 13 MRSA Therapeutics March ket - The UK (2005-2010) 23
III. 14 MRSA Therapeutics March ket Forecasted data - The UK (2010-2017) 24
III. 15 MRSA Therapeutics March ket - Japan (2005-2010) 25
III. 16 MRSA Therapeutics March ket Forecasted data - Japan (2010-2017) 26
III. 17 Drivers and Barriers for the MRSA March ket 27
III. 17.1 MRSA Therapeutics March ket Drivers 27
III. 17.2 MRSA Therapeutics March ket Restraints 27
III. 18 Opportunity and Unmet Need 28
III. 19 Key Takeaway 29

IV MRSA Therapeutics - Competitive Assessment 30
IV. 1 Overview 30
IV. 2 Strategic Competitor Assessment 30
IV. 3 Product Profile for the Major March ket Products in the MRSA March ket 32
IV. 3.1 Vancomycin 32
IV. 3.2 Zyvox (Linezolid) 33
IV. 3.3 Cubicin (Daptomycin) 34
IV. 3.4 Vibativ (Televancin) 35
IV. 3.5 Tygacil (Tigecycline) 36
IV. 3.6 Synercid (Qinupristin+Dalfopristin) 37
IV. 4 MRSA Therapeutics - Major March keted Products Comparison 39
IV. 5 Key Takeaway 39

V MRSA Therapeutics - Pipeline Assessment 40
V. 1 Overview 40
V. 2 Strategic Pipeline Assessment 40
V. 3 MRSA Therapeutics March ket - Pipeline Assessment by Phase of Development 41
V. 3.1 MRSA - Phase III Pipeline 41
V. 3.2 MRSA Therapeutics March ket - Phase II Pipeline 41
V. 3.3 MRSA Therapeutics March ket - Phase I Clinical Pipeline 42
V. 3.4 MRSA Therapeutics March ket - Preclinical Pipeline 42
V. 3.5 MRSA Therapeutics March ket - Discovery Pipeline 42
V. 4 MRSA Therapeutics - Pipeline by Mechanism of Action 43
V. 5 Technology Trends Analytical Framework 45
V. 6 Methicillin-resistant Staphylococcus Aureus March ket - Most Promising Drugs Under Clinical Development 47
V. 7 Most Promising Drug Profiles 48
V. 7.1 Ceftobiprole 48
V. 7.2 Teflaro (Ceftaroline) 49
V. 7.3 Torizolid phosphate (TR-701, DA-7218) 50
V. 8 Key Takeaway 51

VI MRSA Therapeutics - Clinical Trials Mapping 52
VI. 1 Clinical Trials by Region/Country (US, EU-5 and Japan) 52
VI. 2 Clinical Trials by Phase of Clinical Development 53
VI. 3 Clinical Trials by Trial Status 54
VI. 4 Key Sponsors 55
VI. 5 Brief Profiles of Top Ten Firms Participating in Therapeutics Clinical Trials 56

VII MRSA Therapeutics - Strategic Assessment 57
VII. 1 Key Events Impacting the Future March ket 57
VII. 2 Future March ket Competition Scenario 58

VIII MRSA Therapeutics - Future Players 60
VIII. 1 Introduction 60
VIII. 2 Firms Profiles 61
VIII. 2.1 Takeda Pharmaceutical Firms Limited 61
VIII. 2.2 Merck and Co., Inc. 65
VIII. 2.3 Basilea Pharmaceuticals 70
VIII. 2.4 Forest Laboratories 71
VIII. 2.5 The Medicines Firms 74
VIII. 2.6 Nabriva Therapeutics AG 76
VIII. 2.7 TrioBiotics Pharma AG 77
VIII. 2.8 AstraZeneca PLC 78
VIII. 2.9 GlaxoSmithKline plc 82
VIII. 2.10 e-Therapeutics plc 87
VIII. 2.11 Tabular Presentation Details of Other Firms in the Pipeline 89
VIII. 2.12 Key Takeaway 91

IX MRSA Therapeutics - Licensing and Partnership Deals 92

X MRSA Therapeutics: Appendix 95
X. 1 Definitions 95
X. 2 Acronyms 95
X. 3 Research Methodology 96
X. 3.1 Coverage 96
X. 3.2 Secondary Research 97
X. 3.3 Forecasted data ing 97
X. 3.4 Primary Research 100
X. 3.5 Expert Panel Validation 100
X. 4 Contact Us 100
X. 5 Disclaimer 100
X. 6 Bibliography 101

1.1 List of Data tables
Data table 1: Epidemiologic Classification of Invasive MRSA 7
Data table 2: Comparison of Risk Factors Associated with HA-MRSA and CA-MRSA Infection 7
Data table 3: MRSA Therapeutics March ket, Global, Sales (USD Million), 2005-2010 11
Data table 4: MRSA Therapeutics, Major March ket, Global, Forecasted data (USD Million), 2010-2017 12
Data table 5: MRSA Therapeutics March ket, The US, Sales (USD Million), 2005-2010 13
Data table 6: MRSA Therapeutics March ket, The US, Forecasted data s (USD Million), 2010-2017 14
Data table 7: MRSA Therapeutics, France, Sales (USD Million), 2005-2010 15
Data table 8: MRSA Therapeutics March ket, France, Forecasted data s (USD Million), 2010-2017 16
Data table 9: MRSA Therapeutics, Germany, Sales (USD Million), 2005-2010 17
Data table 10: MRSA Therapeutics March ket, Germany, Forecasted data s (USD Million), 2010-2017 18
Data table 11: MRSA Therapeutics, Spain, Sales (USD Million), 2005-2010 19
Data table 12: MRSA Therapeutics March ket, Spain, Forecasted data s (USD Million), 2010-2017 20
Data table 13: MRSA Therapeutics, Italy, Sales (USD Million), 2005-2010 21
Data table 14: MRSA Therapeutics March ket, Italy, Forecasted data s (USD Million), 2010-2017 22
Data table 15: MRSA Therapeutics, The UK, Sales (USD Million), 2005-2010 23
Data table 16: MRSA Therapeutics March ket, The UK, Forecasted data s (USD Million), 2010-2017 24
Data table 17: MRSA Therapeutics, Japan, Sales (USD Million), 2005-2010 25
Data table 18: MRSA Therapeutics March ket, Japan, Forecasted data s (USD Million), 2010-2017 26
Data table 19: MRSA Therapeutics March ket, Global, Vancomycin Sales (USD Million), from 2005 to 2010 32
Data table 20: MRSA Therapeutics March ket, Global, Zyvox Sales (USD Million), from 2005 to 2010 34
Data table 21: MRSA Therapeutics March ket, Global, Cubicin Sales (USD Million), from 2005 to 2010 35
Data table 22: MRSA Therapeutics March ket, Global, Vibativ Sales (USD Million), from 2005 to 2010 36
Data table 23: MRSA Therapeutics March ket, Global, Tygacil Sales (USD Million), from 2005 to 2010 37
Data table 24: MRSA Therapeutics March ket, Global, Synercid Sales (USD Million), from 2005 to 2010 38
Data table 25: Major March keted Products Comparison in MRSA Therapeutics March ket, 2010 39
Data table 26: MRSA Therapeutics - Phase III Pipeline, 2010 41
Data table 27: MRSA Therapeutics - Phase II Pipeline, 2010 41
Data table 28: MRSA Therapeutics - Phase I Pipeline, 2010 42
Data table 29: MRSA Therapeutics - Preclinical Pipeline, 2010 42
Data table 30: MRSA Therapeutics - Discovery Pipeline, 2010 42
Data table 31: MRSA Therapeutics March ket - Most Promising Drugs Under Clinical Development, 20 47
Data table 32: MRSA Therapeutics - Clinical Trials by Country, 2010 52
Data table 33: MRSA Therapeutics, Major March kets - Clinical Trials by Phase, 2010 53
Data table 34: MRSA Therapeutics, Major March kets, Clinical Trials by Development Status, 2010 54
Data table 35: MRSA Therapeutics, Major March kets, Key Sponsors, 2010 55
Data table 36: MRSA Therapeutics, Major March kets, Clinical Trials of Top Ten Firms by Phase, 2010 56
Data table 37: Takeda Deals, Alliances and Partner agreements 62
Data table 38: Takeda Pipeline Products 64
Data table 39: Merck and Co. Deals, Alliances and Partner agreements 67
Data table 40: Merck Pipeline Products 69
Data table 41: Basilea Deals, Alliances and Partner agreements 70
Data table 42: Basilea Pipeline Products 70
Data table 43: Forest Deals, Alliances and Partner agreements 72
Data table 44: Forest Pipeline Products 73
Data table 45: The Medicine Firms Deals, Alliances and Partner agreements 75
Data table 46: The Medicine Firms Pipeline Products 75
Data table 47: Nabriva Deals, Alliances and Partner agreements 76
Data table 48: Nabriva Pipeline Products 76
Data table 49: TrioBiotics Deals, Alliances and Partner agreements 77
Data table 50: TrioBiotics Pipeline Products 77
Data table 51: Astrazeneca Deals, Alliances and Partner agreements 79
Data table 52: Astrazeneca Pipeline Products 81
Data table 53: GlaxoSmithKline Deals, Alliances and Partner agreements 83
Data table 54: GlaxoSmithKline Pipeline Products 86
Data table 55: e-Therapeutics Deals, Alliances and Partner agreements 88
Data table 56: e-Therapeutics Pipeline Products 88
Data table 57: MRSA Therapeutics - Other Firms in the Pipeline, 2010 89
Data table 58: MRSA Therapeutics, Global, Deals, 2010 92

1.2 List of Charts
Chart 1: Treatment and Management Pattern for MRSA Infected Outpatients 9
Chart 2: MRSA Therapeutics March ket, Global, Sales (USD Million), 2005-2010 11
Chart 3: MRSA Therapeutics March ket, Global, Forecasted data (USD Million), 2010-2017 12
Chart 4: MRSA Therapeutics March ket, The US, Sales (USD Million), 2005-2010 13
Chart 5: MRSA Therapeutics March ket, The US, Forecasted data (USD Million), 2010-2017 14
Chart 6: MRSA Therapeutics March ket, France, Sales (USD Million), 2005-2010 15
Chart 7: MRSA Therapeutics March ket, France, Forecasted data (USD Million), 2010-2017 16
Chart 8: MRSA Therapeutics March ket, Germany, Sales (USD Million), 2005-2010 17
Chart 9: MRSA Therapeutics March ket, Germany, Forecasted data (USD Million), 2010-2017 18
Chart 10: MRSA Therapeutics March ket, Spain, Sales (USD Million), 2005-2010 19
Chart 11: MRSA Therapeutics March ket, Spain, Forecasted data (USD Million), 2010-2017 20
Chart 12: MRSA Therapeutics March ket, Italy, Sales (USD Million), 2005-2010 21
Chart 13: MRSA Therapeutics March ket, Italy, Forecasted data (USD Million), 2010-2017 22
Chart 14: MRSA Therapeutics March ket, The UK, Sales (USD Million), 2005-2010 23
Chart 15: MRSA Therapeutics March ket, The UK, Forecasted data (USD Million), 2010-2017 24
Chart 16: MRSA Therapeutics March ket, Japan, Sales (USD Million), 2005-2010 25
Chart 17: MRSA Therapeutics March ket, Japan, Forecasted data (USD Million), 2010-2017 26
Chart 18: Opportunity and Unmet Need in the MRSA Therapeutics March ket 28
Chart 19: Strategic Competitor Assessment, 2010 31
Chart 20: MRSA Therapeutics - Clinical Pipeline by Mechanism of Action, 2010 43
Chart 21: MRSA Therapeutics March ket - Pipeline by Phase of Development, 2010 44
Chart 22: Technology Trends Analytics Framework, 2010 45
Chart 23: Technology Trends Analytics Framework - Description, 2010 46
Chart 24: MRSA Therapeutics - Clinical Trials by Country, 2010 52
Chart 25: MRSA Therapeutics, Major March kets - Clinical Trials by Phase, 2010 53
Chart 26: MRSA Therapeutics, Major March kets, Clinical Trials by Development Status, 2010 54
Chart 27: MRSA Therapeutics, Major March kets, Key Sponsors, 2010 55
Chart 28: MRSA Therapeutics, Major March kets, Clinical Trials of Top Ten Firms by Phase, 2010 56
Chart 29: MRSA Therapeutics March ket, Drivers and Restraints 2010 57
Chart 30: Implications for Future March ket Competition in the MRSA Therapeutics March ket, 2010 58
Chart 31: MRSA Therapeutics March ket - Clinical Pipeline by Firms, 2010 60
Chart 32: MRSA Therapeutics March ket - Clinical Pipeline by Firms, 2010 99

Companies Mentioned
Takeda Pharmaceutical Firms Limited
Merck and Co., Inc.
Basilea Pharmaceuticals
Forest Laboratories
The Medicines Firms
Nabriva Therapeutics AG
TrioBiotics Pharma AG
AstraZeneca PLC
GlaxoSmithKline plc
e-Therapeutics plc

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • April 2014
  • by Global Markets Direct

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Corcept Therapeutics Incorporated - Product Pipeline Review - 2014', provides an overview of the Corcept ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.